Table 2.
Studies reporting systemic and local adverse effects in imiquimod treatment for cervical intraepithelial neoplasia.
| Study | Study design | Treatment | Adverse effects |
Serious adverse events | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Systemic adverse effects |
Local adverse effects |
|||||||||||
| Head-ache | Fever | Fatigue | Myalgia | Vaginal discharge | Vaginal bleeding | Vulvar pruritus | Vulvar pain | Vaginal edema | ||||
| Grimm et al. [8] | RCT | Imiquimod group n = 30 | 25 (83) | 29 (97) | 23 (77) | – | – | 28 (93) | 16 (53) | No | ||
| Placebo group n = 29 | 6 (21) | 12 (34) | 3 (10) | 11 (38) | 3 (10) | |||||||
| Pachman et al. [9] | PS | Imiquimod n = 28 | 7 (25) | 5 (18) | 13 (46) | 15 (54) | 9 (32) | 1 (4) | – | – | No | |
| ST n = 28 | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | ||||||
| Lin et al. [10] | RS | Entire cohort n = 72 | – | 3 (4) | 2 (3) | 1 (2) | 7 (10) | – | 3 (4) | 2 (3) | – | No |
RCT = randomised controlled trial; PS = prospective study; RS = retrospective study; ST = standard treatment.